With Alexion Off the Board, Amarin and Biomarin Are Attractive Acquisition TargetsGuruFocus • 12/24/20
Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical ResultsGlobeNewsWire • 12/14/20
Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020GlobeNewsWire • 12/13/20
VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at National Lipid Association (NLA) Scientific Sessions 2020GlobeNewsWire • 12/07/20
Amarin Corporation plc (AMRN) CEO John Thero Presents at Piper Sandler 32nd Annual Virtual Healthcare Conference Call - (Transcript)Seeking Alpha • 12/02/20
Amarin to Present at Piper Sandler's 32nd Annual Healthcare Conference (Virtual)GlobeNewsWire • 11/24/20
Amarin Shares Topline Data from Partner's Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland ChinaGlobeNewsWire • 11/19/20
Amarin Corporation PLC (AMRN) Presents at Jefferies Virtual London Healthcare Broker Conference Call - (Transcript)Seeking Alpha • 11/19/20
Multiple New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at American Heart Association's Virtual Scientific Sessions 2020GlobeNewsWire • 11/18/20
Amarin Corporation plc (AMRN) Presents at Stifel Virtual Healthcare Conference (Transcript)Seeking Alpha • 11/16/20
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting (CABG) Procedures in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Heart Association's Virtual GlobeNewsWire • 11/13/20
Amarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare ConferencesGlobeNewsWire • 11/11/20
Amarin Corporation plc (AMRN) CEO John Thero on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/05/20
Amarin Reports Third Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 11/05/20
These 3 Stocks Are Trading at Ludicrous P/E Ratios. Should Investors Avoid Them?The Motley Fool • 11/02/20
Amarin's Vascepa Shows Reduced Cardiovascular Events in Kidney Patients in Latest StudyThe Motley Fool • 10/26/20